Youngy Health Co., Ltd. (SHE:300247)
China · Delayed Price · Currency is CNY 3.230
-0.050 (-1.52%)
Oct 30, 2026, 3:04 PM CST
Youngy Health Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 868.68 | 925.21 | 681.18 | 521.77 | 453.79 | 516.31 |
Other Revenue | 7.94 | 7.94 | 7.61 | 7.68 | 9.53 | 10.19 |
| 876.63 | 933.15 | 688.79 | 529.45 | 463.32 | 526.5 | |
Revenue Growth | 1.36% | 35.48% | 30.10% | 14.27% | -12.00% | 2.42% |
Cost of Revenue | 499.72 | 600.83 | 472.78 | 363.03 | 354.61 | 408.31 |
Gross Profit | 376.9 | 332.32 | 216.01 | 166.42 | 108.71 | 118.19 |
Selling, General & Admin | 192.04 | 176.07 | 135.12 | 119.56 | 105.05 | 97.46 |
Research & Development | 13.5 | 12.27 | 11.7 | 9.06 | 10.97 | 13.52 |
Other Operating Expenses | 8.64 | 6.32 | 4.82 | 4.8 | 4.6 | 3.94 |
Operating Expenses | 214.1 | 195.32 | 153.2 | 133.48 | 121.52 | 105.9 |
Operating Income | 162.8 | 137 | 62.81 | 32.94 | -12.81 | 12.29 |
Interest Expense | - | - | - | - | -0 | - |
Interest & Investment Income | 10.82 | 14.44 | 16.53 | 11.88 | 136 | 9.74 |
Currency Exchange Gain (Loss) | -5.5 | -5.5 | 3.06 | 2.34 | 9.05 | -3.45 |
Other Non Operating Income (Expenses) | -1.69 | -2.51 | -0.98 | -1.8 | -0.18 | 1.09 |
EBT Excluding Unusual Items | 166.43 | 143.43 | 81.42 | 45.36 | 132.05 | 19.66 |
Gain (Loss) on Sale of Investments | 5.73 | 0.51 | 5.66 | 13.32 | 3.38 | 15.86 |
Gain (Loss) on Sale of Assets | 0.13 | -0.09 | 0.01 | -0.5 | 0.59 | 0.03 |
Asset Writedown | -0.57 | -0.07 | -0.95 | -0.38 | -0.31 | 0.03 |
Other Unusual Items | 3.78 | 4.15 | 2.01 | 1.96 | 0.68 | 2.19 |
Pretax Income | 175.51 | 147.93 | 88.15 | 59.76 | 136.39 | 37.77 |
Income Tax Expense | 64.08 | 39.79 | 22.1 | 17.84 | 3.06 | 6.32 |
Earnings From Continuing Operations | 111.43 | 108.15 | 66.06 | 41.92 | 133.33 | 31.45 |
Minority Interest in Earnings | -41.59 | -33.34 | -19.2 | -15.34 | -7.02 | -7.25 |
Net Income | 69.84 | 74.8 | 46.85 | 26.58 | 126.31 | 24.2 |
Net Income to Common | 69.84 | 74.8 | 46.85 | 26.58 | 126.31 | 24.2 |
Net Income Growth | -9.24% | 59.65% | 76.26% | -78.95% | 421.87% | - |
Shares Outstanding (Basic) | 831 | 831 | 781 | 886 | 789 | 807 |
Shares Outstanding (Diluted) | 831 | 831 | 781 | 886 | 789 | 807 |
Shares Change | 6.35% | 6.43% | -11.87% | 12.24% | -2.15% | -1.81% |
EPS (Basic) | 0.08 | 0.09 | 0.06 | 0.03 | 0.16 | 0.03 |
EPS (Diluted) | 0.08 | 0.09 | 0.06 | 0.03 | 0.16 | 0.03 |
EPS Growth | -14.66% | 50.00% | 100.00% | -81.25% | 433.33% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 27.27 | 105.84 | 42.2 | 80.53 | -46.72 | 4.6 |
Free Cash Flow Per Share | 0.03 | 0.13 | 0.05 | 0.09 | -0.06 | 0.01 |
Gross Margin | 42.99% | 35.61% | 31.36% | 31.43% | 23.46% | 22.45% |
Operating Margin | 18.57% | 14.68% | 9.12% | 6.22% | -2.77% | 2.33% |
Profit Margin | 7.97% | 8.02% | 6.80% | 5.02% | 27.26% | 4.60% |
Free Cash Flow Margin | 3.11% | 11.34% | 6.13% | 15.21% | -10.08% | 0.87% |
EBITDA | 178.54 | 152.97 | 79.09 | 50.16 | 5.45 | 29.49 |
EBITDA Margin | 20.37% | 16.39% | 11.48% | 9.47% | 1.18% | 5.60% |
D&A For EBITDA | 15.74 | 15.98 | 16.28 | 17.22 | 18.27 | 17.2 |
EBIT | 162.8 | 137 | 62.81 | 32.94 | -12.81 | 12.29 |
EBIT Margin | 18.57% | 14.68% | 9.12% | 6.22% | -2.77% | 2.33% |
Effective Tax Rate | 36.51% | 26.90% | 25.07% | 29.85% | 2.25% | 16.73% |
Revenue as Reported | 281.25 | 933.15 | 688.79 | 529.45 | 463.32 | 526.5 |
Advertising Expenses | - | 9.7 | 11.26 | 8.01 | 7.84 | 6.1 |